NKTR as reported
Nektar Therapeutics reported $56M of revenue over the trailing twelve months, −36% on the year before. 10 reported series are charted on this page, each one as filed.
$56M
Revenue, trailing twelve months · to Q1 2026 · −36% against the twelve months before
- Net Income
- −$158M
Net Income · +19% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$204M
Free Cash Flow · +14% year on year · trailing twelve months to Q1 2026
- Op Margin
- −270%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $56M | −36% | Q1 2026 |
| Net Income | −$158M | +19% | Q1 2026 |
| EPS | −$8.23 | −13% | Q1 2026 |
| Gross Margin | 100% | n/a | Q4 2025 |
| Op Margin | −270% | n/a | Q1 2026 |
| Net Margin | −313% | n/a | Q1 2026 |
| ROE | 38% | n/a | Q1 2026 |
| ROA | −45% | n/a | Q1 2026 |
| Free Cash Flow | −$204M | +14% | Q1 2026 |
| P/E | 165 | n/a | Q1 2019 · 28 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Nektar Therapeutics (NKTR) - Revenue & ProfitRevenue & ProfitNektar Therapeutics (NKTR)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com